PV Bulletin

SAHPRA Consultation on Transition to VigiFlow Platform

SAHPRA invites HCRs and CROs to adapt to a new electronic reporting system for safety data.

Primary source: Redirecting

PV Impact Brief

Urgency: HighConfidence: high

What changed

Introduction of the VigiFlow platform as the mandatory electronic reporting portal for submitting adverse events (AEs) and serious adverse events (SAEs) in South Africa.

Why it matters

This transition to a fully digital reporting platform enhances the efficiency and accuracy of safety data submissions, aligning South Africa with international pharmacovigilance standards.

Action needed

Holders of Certificates of Registration and Clinical Research Organisations must update their safety databases and reporting workflows to comply with the new electronic reporting requirements for AEs and SAEs.

Relevant for
Regulatory Intelligence LeadQPPV
Processes impacted
ICSRCountry Compliance
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Consultation
Policy status
consultation
Publication date
2026-07-22
Policy change
SAHPRA has launched a consultation on transitioning to the VigiFlow platform for electronic reporting of safety data. This initiative aims to digitalize pharmacovigilance and clinical trial safety reporting (ICSRs and SUSARs) in South Africa, aligning with international E2B standards.

Key changes

Introduction of VigiFlow as the primary electronic reporting portal; adoption of E2B reporting standards; updated technical specifications for submission of ICSRs from MAHs and SUSARs from clinical trial sponsors.

Affected workflows

ICSRCountry Compliance

Responsible groups

Pharmacovigilance OperationsIT / Database ManagementClinical Safety

PV impact

MAHs and clinical trial sponsors in South Africa will need to update their safety databases and reporting workflows to integrate with the VigiFlow platform. This represents a significant shift from current manual or paper-based processes to a fully digital E2B environment.

View regulator source

Source document details

Exact policy details

Document Number
PV02-2026/27
Applies to: Relevant to Holders of Certificates of Registration (HCRs) and Clinical Research Organisations (CROs)
Source text mentions 'Document Number: PV02-2026/27' · p. 1 · High · Source
Version
1
Applies to: Document version applicable for the consultation
Source text mentions 'Version: 1' · p. 1 · High · Source
Date Updated
22/07/2026
Applies to: Date of the latest update for the documentation
Source text mentions 'Date Updated: 22/07/2026' · p. 1 · High · Source
Consultation Meeting
Invitation for consultation
Applies to: Holders of Certificates of Registration and Clinical Research Organisations
Source text states 'invites all Holders of Certificates of Registration (HCRs) and Clinical Research Organisations (CROs) responsible for submitting adverse events...' · p. 1 · High · Source

Extracted documents

Evidence and confidence

Confidence: highSource updated: Jul 22, 2026

Full briefing

Practical implication

Holders of Certificates of Registration and Clinical Research Organisations must update their safety databases and reporting workflows to comply with the new electronic reporting requirements for AEs and SAEs.

The South African Health Products Regulatory Authority (SAHPRA) has initiated a consultation that requires all Holders of Certificates of Registration (HCRs) and Clinical Research Organisations (CROs) to transition to the VigiFlow platform for electronic safety reporting. This shift aims to modernize pharmacovigilance practices according to international E2B standards, necessitating updates to current manual reporting processes.

What changed: Introduction of the VigiFlow platform as the mandatory electronic reporting portal for submitting adverse events (AEs) and serious adverse events (SAEs) in South Africa.

Why it matters: This transition to a fully digital reporting platform enhances the efficiency and accuracy of safety data submissions, aligning South Africa with international pharmacovigilance standards.

Practical implication: Holders of Certificates of Registration and Clinical Research Organisations must update their safety databases and reporting workflows to comply with the new electronic reporting requirements for AEs and SAEs.

View original source

Published from the Firecrawl policy change extraction pipeline.

Related updates for your role

publicEuropean Medicines Agency (EMA) · EU · Updated Jul 22, 2026

Release of CTIS Training Module 18: How to create and submit an annual safety report (ASR)

Urgency: High

Clinical trial sponsors must update their internal SOPs for safety reporting and ensure staff are trained on the new submission steps for ASRs through the CTIS platform.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Process Change / Guidance
Read impact briefarrow_forward
publicEuropean Medicines Agency · EU · Updated Jul 22, 2026

Revision of Guideline on Similar Biological Medicinal Products

Urgency: High

MAHs must prepare for updated risk management plans and post-marketing surveillance processes, reflecting the revised data requirements and definitions for biosimilars as per the NPL.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead, Labeling Lead
verifiedRegulatory action: Consultation
Read impact briefarrow_forward
publicVeterinary Medicines Directorate (VMD) · United Kingdom · Updated Jul 10, 2026

New digital service for MAHs to report safety data

Urgency: High

MAHs are encouraged to transition to the new digital service for all pharmacovigilance reporting and utilize the feedback function during the beta phase to improve the service.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact3 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: News / Procedural Update
Read impact briefarrow_forward
publicANSM, France · France · Updated Jul 21, 2026

Renewal of Compassionate Use Framework for Methotrexate

Urgency: High

Healthcare providers must ensure patient registrations and comply with adverse event reporting as per the renewed compassionate use framework, which includes the collection and analysis of safety data.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Executive Order / Decision
Read impact briefarrow_forward